Mold-tek's lube guidance flips: from stabilised to 17% drop
EBITDA per kg hit a record ₹46.7 in Q1, but a fresh lube disruption, unexplained capex increase and a repurposed plant raise doubts about forecast reliability.
What's new
- Q1 EBITDA per kg hit ₹46.7, above the ₹40.7 full-year benchmark.
- Lube volumes fell 17% on base oil unavailability at private customers.
- Pharma revenue grew 41% and food/FMCG volumes rose 24.2%.
- Capex guidance for FY25 raised to ~₹90cr from ₹80-85cr in prior calls.
Themes from the call
Demand
Lube demand disrupted by customer base oil supply, but paint (+10.8%), food/FMCG (+24.2%) and pharma (+38%) volumes strong.
Margins
Record EBITDA per kg driven by high-value pharma and food mix, raw material pass-through and Hyderabad consolidation benefits.
Capital allocation
FY25 capex guided ~₹90cr (up from ₹80-85cr) with ₹25-30cr for pharma; new plant repurposed from pharma to medical devices.
Guidance watch
- FY25 volume growth 10-12%, with paint at 10-15% and food/FMCG at 18-20% CAGR.
- EBITDA per kg target raised to ₹44-45 for FY25; ₹45-46 expected in coming quarter.
- Pharma revenue target ₹50-55cr for FY25 vs ₹34cr prior year.
- Lube expected to recover toward zero growth as base oil supply improves.
- Capex now ~₹90cr vs earlier ₹80-85cr; capacity additions 10-12% annually.
Risk flags
- Lube recovery entirely dependent on customer base oil sourcing; management cannot control timing.
- Unexplained ₹5-10cr capex increase and plant repurposing suggest strategy fluidity.
- Q-Pac growth slowed to 2% on customer price sensitivity; recovery to double-digit in Q2 is uncertain.
- Device and pharma timing relies on client validations and IP partner tie-ups.
Key quotes
-
"Having lost all the PSU business now, we may sustain at the current levels in Lubes."
— Mold-tek management, May 2026 call -
"The lube segment has dropped by 17%. It is mainly because of base oil unavailability with a couple of private companies."
— Mold-tek management, July 2026 call
The brief
Mold-tek Packaging's Q1FY26 result is a study in contrasts. EBITDA per kg hit a record ₹46.7, powered by pharma, food and mix improvements. But the lube business — a 17-20% revenue contributor — fell 17% because private customers couldn't secure base oil. That contradicts the May 2026 call, when management said lube volumes had stabilised and would sustain current levels. The explanation shifted from structural demand loss to a supply disruption, which sounds plausible but makes the earlier guidance look optimistic.
Two other inconsistencies add to the credibility gap. The FY27 capex budget crept up to ₹90 crore from the ₹80-85 crore range guided in February and May, with no commentary on what changed. And the new plant, billed as a pharma expansion in May, is now reserved for medical devices — specifically dosing pens and other items. Management says current pharma growth will stay within existing premises, which is fine, but the pivot without explanation leaves investors guessing on capital allocation priorities.
On the positive side, the core thesis is intact. Paint volumes grew 10.8%, food and thin-wall 24.2%, and pharma 41%. EBITDA per kg at ₹46.7 is well above the ₹40.7 full-year benchmark, and management expects to sustain ₹45-46 in the near term. The mix shift toward higher-value categories is driving profitability, and the consolidation benefits from Hyderabad are visible.
The question is how much of the EBITDA improvement is sustainable if lube doesn't recover and Q-Pac remains sluggish. Management's 18-20% EBITDA growth guidance for the rest of FY25 assumes lube normalises. That's a big if, given the uncontrollable base oil supply. The capex and plant repurposing inconsistencies don't inspire confidence either.
Mold-tek's lube turnabout and unexplained capex shift undermine the comfort its record EBITDA per kg would otherwise provide.